94 results
424B5
WVE
Wave Life Sciences Ltd.
8 Dec 23
Prospectus supplement for primary offering
6:06am
are a clinical-stage RNA medicines company, and our business and ability to execute our business strategy are subject to a number of significant … . and foreign governments could adversely affect our business.
We may not be able to execute our business strategy optimally if we are unable to maintain our
424B5
WVE
Wave Life Sciences Ltd.
6 Dec 23
Prospectus supplement for primary offering
4:13pm
Relating to Our Business
We are a clinical-stage RNA medicines company, and our business and ability to execute our business strategy are subject … strategy optimally if we are unable to maintain our existing collaborations or enter into new collaborations with partners that can provide sales, marketing
8-K
EX-99.1
c0x1o2kyh0n4bj
28 Sep 23
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
4:38pm
8-K
EX-99.1
8lsgh
13 Dec 22
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties
7:48am
424B5
75ai6 s94
14 Jun 22
Prospectus supplement for primary offering
9:24am